Can you screen for scFv stability before we build the CAR?

Yes. We use biophysical proxies on soluble scFvs during the screening phase to discard aggregation-prone candidates before you ever clone them into a viral vector.

Are your libraries suitable for bi-specific CARs?

Yes. Our V H H and scFv libraries provide modular binders that are easily linked for dual-target applications (e.g., CD19/CD22) without steric hindrance.

What is the typical timeline?

A standard campaign runs 8-16 weeks from antigen agreement to delivery of ranked, sequenced leads with preliminary biophysical data.

Do you perform the CAR-T functional assays (cytotoxicity)?

Our primary focus is delivering the optimized binder. However, we can perform functional surrogate assays (e.g., cell binding, internalization). For full CAR-T engineering and cytotoxicity, we can partner with your internal team or downstream providers.

CAR-T Therapy Discovery Service by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? FAQ

Creative Biolabs accelerates your CAR-T program by bypassing animal immunization. We utilize premier human antibody libraries and CAR-specific screening strategies to deliver scFv and V_HH candidates that are biophysically stable, non-immunogenic, and functionally tuned for persistence.

CAR-Ready Formats
Discovery directly in scFv or V_HH formats, no conversion loss.

Precision Specificity
Stringent negative selection to eliminate on-target/off-tumor toxicity.

Epitope Diversity
Target membrane-proximal or distal epitopes to tune the immunological synapse.

Start Your Project Today – Request a Quote

Accelerate CAR Development with Bio-Superior Binders

In CAR-T development, the antibody is not a reagent; it is a functional receptor. Using traditional hybridoma or instability-prone libraries often results in scFvs that unfold on the T-cell surface, triggering antigen-independent signaling (tonic signaling) and T-cell exhaustion. Our service addresses this by screening directly from highly stable, fully human scFv and V_HH libraries. We integrate cell-based panning and biophysical triage early in the process to deliver candidates that fold correctly on the membrane, bind with high specificity, and maintain T-cell fitness.

At Creative Biolabs, screening for CAR-T binders is a strategy engineered for cellular outcomes. Our phage and yeast display platforms are tuned to navigate the vastness of our premier human libraries with surgical precision. We employ cell-based panning strategies, alternating between recombinant proteins and tumor cell lines, to ensure binders recognize the antigen in its native conformation.

Ready to Begin? Get Your Personalized Quote

How We Work

Inputs

Target name, preferred format (scFv/V_HH), exclusion criteria (healthy tissue cross-reactivity), and desired affinity range.

Workflow

Fig.1 Antigen Design. (Creative Biolabs AI)

Antigen Design

Fig.2 Enrichment (Panning). (Creative Biolabs AI)

Enrichment (Panning)

Fig.3 Clone Screening. (Creative Biolabs AI)

Clone Screening

Fig.4 Functional Selection. (Creative Biolabs AI)

Functional Selection

Fig.5 Sequence Analytics. (Creative Biolabs AI)

Sequence Analytics

Fig.6 IgG Conversion. (Creative Biolabs AI)

IgG Conversion

Deliverables

Ranked sequences, epitope bins, kinetic data, and biophysical stability profiles.

Let's Talk. Request a Quote for Your Project.

Ready-to-Screen Antibody Libraries

Human Camel Llama Alpaca Humanized V_HH

Antibody Library ID	Display Technology	Library Format	Library Size
HuScL-6 ☆Highly Recommended	pIII-fusion, Phagemid Phage Display	Naïve scFv	2.1×10¹¹
HuScL-3S	pIII-fusion, Phagemid Phage Display	Semi-synthetic scFv	>1.0×10¹¹
HuFabL-4	pIII-fusion, Phagemid Phage Display	Naïve Fab	1.9×10¹⁰
HuFabssL-1	pIII-fusion, Phagemid Phage Display	Naïve & synthetic Fab	1.8×10¹⁰

Find the Perfect Library for Your Target

Case Study: High-Diversity Libraries, High-Impact Outcomes

TCR-like V_HH Discovery for Neoantigen-Targeted CAR-T Therapy

Objective

In the landscape of CAR-T therapy, targeting intracellular antigens via MHC-peptide complexes (pMHC) is a transformative approach. However, distinguishing a Neoantigen (tumor-specific mutation) from a Wild-Type (WT) peptide, which often differs by only a single amino acid, requires extraordinary antibody specificity to avoid off-target toxicity. This case study demonstrates our success in isolating high-affinity, TCR-like V_HH antibodies that specifically recognize a mutant peptide-MHC complex while maintaining zero cross-reactivity with the wild-type counterpart.

Project Workflow & Strategy

To solve the challenge of high structural similarity, we utilized our Premade Synthetic Single Domain Antibody (V_HH) Library and a rigorous, multi-step In-solution Competitive Screening strategy.
Custom Antigen Preparation
Both the Target (MHC-Mutant Peptide) and the Control (MHC-WT Peptide) were produced in-house with stringent QC validation to ensure correct folding and biotinylating efficiency.
Precision Screening Design

Pre-counter Selection
The library was first incubated with biotinylated MHC-WT complexes to deplete any binders to the MHC framework or common self-peptides.

Positive Selection
Enrichment was performed using the biotinylated Target MHC-Mutant complex.

Competitive Elution/Selection
During the incubation, an excess of non-biotinylated Control MHC-WT peptide was introduced as a competitor. This pulls away clones with even slight cross-reactivity, ensuring only mutation-specific binders remain.

Key Results

1. Significant Library Enrichment
The selection process demonstrated a clear exponential increase in the recovery rate across three rounds of panning. The significant rise in output titers from Round 2 to Round 3 indicated a successful convergence toward highly specific binders.
Fig.7 Graph illustrating the library screening outcomes. (Creative Biolabs Original)

Fig.7 Graph illustrating the library screening outcomes. (Creative Biolabs Original)

2. Exceptional Specificity Validation (Soluble ELISA)
From the enriched pool, three lead V_HH candidates were identified. Validation via Soluble ELISA confirmed their TCR-like behavior: they exhibited strong binding signals to the MHC-mutant complex and zero detectable binding to the MHC-WT complex.
Fig.8 Graph displaying the clone validation results. (Creative Biolabs Original)

Fig.8 Graph displaying the clone validation results. (Creative Biolabs Original)

Request a Custom Proposal

Related Services

Fig.9 Antibody Discovery for Immunotherapy. (Creative Biolabs Authorized)

Premade Antibody Library based Antibody Discovery Service for Immune Checkpoint

Premade Antibody Library based Antibody Discovery Service for ADC Therapy

Why Choose Us?

Stability by Design

We prioritize candidates with high thermal stability and low aggregation propensity, directly reducing the risk of tonic signaling caused by scFv self-aggregation on the T-cell surface.

Minimized Immunogenicity

Our libraries utilize validated fully human frameworks, minimizing the risk of anti-drug antibody (ADA) responses and ensuring long-term CAR-T persistence in patients.

Tuned for Serial Killing

We don't just hunt for the tightest binder; we identify the right binder with optimal koff rates to enable efficient serial killing and prevent premature T-cell exhaustion.

V_HH & Multi-Logic Capabilities

Our specialized single-domain antibody libraries are ideal for constructing compact, bi-specific or multi-antigen-logic CARs without the chain-pairing issues of traditional scFvs.

Neoantigen & TCR-like Precision

We possess a proven track record in discriminating amino acid mutations (1-2 aa difference), enabling the isolation of high-specificity binders for complex peptide-MHC (pMHC) targets.

In-house Antigen Expertise

From MHC assembly to site-specific biotinylation, we maintain comprehensive control over protein quality to ensure the highest screening stringency.

Speed to Vector

By bypassing the animal immunization step, we move from target to sequenced, validated leads in as little as 6-8 weeks.

Transparent IP & NGS Data

You retain full ownership of the sequences. We provide complete NGS datasets, empowering your team to mine for backup candidates or expand your IP portfolio.

Customize Your Package - Get Pricing

Ready to move fast? Creative Biolabs will scope your target, advise on best library and protocol, and get screening up and running as soon as possible.

FAQ

Can you screen for scFv stability before we build the CAR?
Yes. We use biophysical proxies on soluble scFvs during the screening phase to discard aggregation-prone candidates before you ever clone them into a viral vector.
Are your libraries suitable for bi-specific CARs?
Yes. Our V_HH and scFv libraries provide modular binders that are easily linked for dual-target applications (e.g., CD19/CD22) without steric hindrance.
What is the typical timeline?
A standard campaign runs 8-16 weeks from antigen agreement to delivery of ranked, sequenced leads with preliminary biophysical data.
Do you perform the CAR-T functional assays (cytotoxicity)?
Our primary focus is delivering the optimized binder. However, we can perform functional surrogate assays (e.g., cell binding, internalization). For full CAR-T engineering and cytotoxicity, we can partner with your internal team or downstream providers.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: